Drug Discovery World

APRIL 13, 2023

Sixteen speakers will showcase the latest drug discovery research in this vast topic based on tiny particles. The post SLAS Europe 2023 reveals details of Biology Unveiled track appeared first on Drug Discovery World (DDW). Another option is to attend a Special Interest Group meeting. View the Full SLAS Europe 2023 Programme.

In-Vitro 52

In-Vitro Genome Genomics Engineer 52

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. months vs. 15.2 months, p = 0.01).

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. OR: The presentations at ESMO TAT 2024 highlighted our advances in targeted and more personalised anti-tumour therapies. MT: What data did you present at the conference? MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

APRIL 8, 2024

Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Pharmaceutical Technology

AUGUST 11, 2022

Using data from the UK Biobank database, genomic sequencing data for 360,000 individuals were obtained and the findings were confirmed in animal models that demonstrated a higher expression of the INHBE gene in obese monkeys when compared to more lean monkeys.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

Drug Discovery World

JANUARY 17, 2024

Challenges in the Oncology Clinical Trials Space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 2040 1,2.

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

MARCH 23, 2023

Consistent with first-generation PI3Kdinhibitors, roginolisib inhibits the in vitro growth of lymphoma cells. iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications.

Research 98

Research In-Vitro Clinical Research Genome 98

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

DECEMBER 14, 2020

”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. . DALLAS , Dec. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Pfizer’s COVID-19 therapy Paxlovid, for example, targets Mpro.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

Drug Discovery World

DECEMBER 8, 2023

Investments in AI and related technologies are driving this seismic shift where modest improvements in early-stage drug development success rates enabled by AI and machine learning could lead to an additional 50 novel therapies over 10 year s, a more than $50 billion opportunity.

Gene Therapy 64

Gene Therapy Gene In-Vitro Development 64

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

XTalks

MAY 12, 2022

Clinical immunosuppression drugs such as ciclosporin, tacrolimus, sirolimus, prednisone and everolimus are administered to the recovering recipients to prevent transplant rejection. received approval by the US Food and Drug Administration (FDA). Cytomegalovirus (CMV) Infection in Transplant Recipients.

In-Vitro 52

In-Vitro DNA Development Genome 52

Drug Discovery World

JUNE 12, 2023

Then, we move forward with what are called Investigational New Drug enabling studies. At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research.

Research 52

Research In-Vitro Doctors Doctor 52

pharmaphorum

OCTOBER 29, 2020

insitro uses machine-learning technology to discover novel drug targets and patient segments. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Development 45

Development DNA In-Vitro Genome 45

Drug Discovery World

DECEMBER 13, 2022

Encouraged by their in vitro findings, the research team is now proposing translational work by setting up large-scale clinical trials involving patients with FCMD. . The post RNA interference method could treat muscular dystrophy appeared first on Drug Discovery World (DDW). Modifying RNA function.

RNA 52

RNA Genetics Gene In-Vitro 52

Drug Discovery World

APRIL 21, 2023

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

Drug Discovery World

NOVEMBER 8, 2023

Antibody-based cancer therapies The second track of PEGS Europe 2023 is ‘Antibody-based cancer therapies’, which will feature a range of sessions made up of presentations, talks and posters which cover antibody drug conjugates (ADCs), intracellular, bispecific, and logic-gated antibodies, and conditionally active biologics.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

FEBRUARY 28, 2023

Finally, dosing and timing may be controlled simply by adjusting the amount of mRNA delivered to the cells, rather than relying on inducible systems that are integrated into the genome. Approximately 7,000 rare and ultra-rare diseases have been described, and yet, 90% have no approved therapeutic options 1.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

The Pharma Data

NOVEMBER 17, 2021

Nasdaq VIR) moment blazoned US government contracts totalling roughly$ 1 billion (1) (USD) to buy sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Exigency Use Authorization (EUA) in May 2021. 1.617.2), Delta Plus (AY.1 2) and Mu (B.1.621).

Antibody 52

Antibody In-Vitro Vaccination Vaccine 52

The Pharma Data

JANUARY 11, 2021

Food and Drug Administration (FDA) issued an official alert stating that it could trigger false negatives in COVID-19 tests. . I-SPY COVID-19 is assessing multiple drugs for critical COVID-19 hospitalized or ICU patients. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

FDA Law Blog

MAY 25, 2022

It is not uncommon for some in vitro diagnostic tests to suffer from poor positive predictive value, in part due to the rarity of the disease. Earlier this week, the Senate HELP Committee released a discussion draft of the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (or FDASLA) (available here ).

Regulation 40

Regulation Genetics In-Vitro Development 40

The Pharma Data

NOVEMBER 23, 2021

Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. The safety profile was similar for Polivy plus R-CHP versus R-CHOP.1 Roche’s Chief Medical Officer and Head of Global Product Development. “

Antibody 52

Antibody In-Vitro Development Genome 52

The Pharma Data

JANUARY 24, 2021

Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. The drug appears to inhibit IL-6, IL-1beta, TNF-alpha and other pro-inflammatory cytokines and chemokines. Read on to see. COVID-19-Related. It also has robust antimicrobial properties.

Trials 52

Trials Allergies In-Vitro Antibody 52

XTalks

DECEMBER 11, 2023

Their groundbreaking Tablo Hemodialysis System, cleared by the US Food and Drug Administration (FDA) for use from hospital to home, signifies a monumental leap in technology, revolutionizing the dialysis experience for patients while streamlining operational aspects for providers. In 2021, Axonics achieved an impressive revenue of $180.3

Production 110

Production Sales In-Vitro Development 110

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

OCTOBER 17, 2022

In today’s quest to accelerate time to market for novel drugs, part of the success formula requires leveraging discovery data with more precision and speed, and earlier in the process. The ability to do this is essential at each of the three steps in the drug discovery process – create, test, and choose.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S.

Antibody 52

Antibody In-Vitro Trials Development 52

The Pharma Data

NOVEMBER 11, 2021

” In February, the EMA’s CHMP initiated a rolling review of Ronapreve, one of the nonsupervisory tools used to speed up the assessment of a promising drug during a public health exigency. .”People A final decision regarding the blessing of Ronapreve is anticipated from the European Commission in the near future.

In-Vitro 40

In-Vitro Antibody Medicine Development 40

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S.

Antibody 52

Antibody Medicine In-Vitro Trials 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

NOVEMBER 12, 2021

EU marketing authorisation follows approvals in Japan, the United Kingdom and Australia Approval based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to moderate disease and reduced risk of symptomatic COVID-19 infections in people exposed to the virus.

In-Vitro 40

In-Vitro Medicine Development Marketing 40

XTalks

NOVEMBER 19, 2021

While the aim in many cases is to use biomarkers to assess a patient’s quantitative response to a study drug, it is important to ascertain a link between the drug’s mechanism of action and an ensuing biological effect in order for it to be a reliable readout of drug response.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

DECEMBER 2, 2020

Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. About Progenity. Progenity, Inc. Progenity, Inc.

In-Vitro 40

In-Vitro Sales Containment Production 40

The Pharma Data

SEPTEMBER 6, 2020

We remain committed to finding personalised treatment options for people with cancer based on specific genomic or molecular alterations, and we look forward to partnering with Blueprint Medicines to further explore the potential of Gavreto across multiple RET-altered tumour types.”. months, not reached). 2 The most common adverse reactions (?

FDA Approval 52

FDA Approval Medicine In-Vitro Genetics 52

The Pharma Data

MARCH 26, 2021

New in vitro data from pseudotyped virus assays published online in bioRxiv in March 2021 support this hypothesis as they demonstrate that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants. GlaxoSmithKline plc and Vir Biotechnology, Inc.

Antibody 52

Antibody Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 2, 2020

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. NASDAQ: PROG) today announced the pricing of its offering of $75.0 The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. million principal amount of notes. per share of common stock.

Sales 40

Sales In-Vitro Containment Development 40